Monitoring:
- Medical Monitoring (including 24/7 Medical Monitor
coverage)
- To enhance regulatory compliance, our Medical Monitor is
assigned to every project and is accessible 24 hours a day, every
day to handle critical situations.
- Clarifying inclusion/exclusion criteria with the
investigator.
- Providing consultation for potential safety issues or medical
concerns regarding the clinical study.
Clinical Monitoring
- ClinQua CRAs perform comprehensive site management and
monitoring activities to include the following types of monitoring
visits:
- Pre study qualification visits
- Initiation visits
- Interim monitoring visits
- Close out visits
All activities are performed in accordance with ICH-GCP to
ensure all investigational sites are compliant with all applicable
regulations and protocol requirements.
The paramount responsibility of CLINQUA CRAs is to
ensure patient rights, safety and data integrity. This is
accomplished through ongoing review of the following:
- Informed consent process
- IRB/IEC approval
- Ensuring proper AE and SAE reporting and
- documented follow up
- Adherence to the protocol
- 100% source documentation verification and data query
clarification
- Investigational product administration and accountability
- Protocol Compliance
- Site training and support
CLINQUA CRAs ensure ongoing site compliance via the
continual ongoing review of the following:
- Site staff qualifications and experience
- Site staffing, facilities, storage and equipment
- Accessibility and eligibility of subjects
- Review and retrieval of regulatory documents
- Accurate and timely completion of all CRF and
- source data
In addition to on-site responsibilities each CRA is responsible
for site management documentation and follow-up activities to
ensure that site staff remains motivated and focused.
These activities include the following:
- Site Visit Report and follow-up letters
- Review of safety reports
- Providing site training and support through communications
- Generation of status reports
- Maintenance of tracking tools/logs
- Facilitation of DCF resolution
CLINQUA CRAs complete comprehensive site visit reports and
follow-up letters which are provided to the CLINQUA project
management team within 10 working days of the visit; however, all
urgent issues are immediately reported to project management. The
visit reports provided by the CRAs include detailed action plans
for all issues identified and all issues are tracked through to
resolution.
In summary the CLINQUA CRA plays a major role in the successful
conduct of a study. The relationship developed between the CRA and
the site staff is such that there is a focus on open effective
communication with the CRA providing training and support thus
ensuring patient safety, data quality and maximizing patient
enrolment.
Site Qualification (Pre-Study Visits)
CLINQUA's site management and monitoring procedures will be
performed in accordance with ICH-GCP to ensure each investigative
site%92s compliance with regulations and protocol requirements, and
to enhance expeditious enrollment of appropriate patients into the
clinical study. Regulatory documents will be reviewed by the CRA on
an ongoing basis during the study conduct phase, including
verification of signed informed consent forms and investigator IRB
notifications.
The CLINQUA CRA will review the following information at
the pre-study site visit:
- Latest version of the Protocol for this study
- Consent form process
- AE and SAE reporting procedures and contact information
- Case report form completion and maintenance
- Source documentation requirements
- Drug accountability requirements
In addition, to ascertain that an identified investigational
site is qualified to perform this study to CLINQUA's
expectations, the CRA will review the following issues at the study
site and report this "study profile" in a site visit
report to CLINQUA and Sponsor:
- Principal investigator qualifications and experience
- Site staffing, facilities, storage and equipment
- Adequacy of and accessibility to subject population
- Access to source documentation
- IRB and ethics committee issues
- Laboratory and pharmacy certifications and normal ranges (if
applicable)
- Investigator agreement and indemnification issues
- Recommendations for investigational site approval or exclusion
from the study
Sites that have recently had a pre-study site visit performed by
Sponsor or have worked with CLINQUA in the preceding six months may
be exempt from a pre-study site visit. SPONSOR will provide CLINQUA
with a list of any exempt investigators for this study.
Site Initiation
Once all regulatory documents and approvals are received, a site
initiation visit will be scheduled for those investigators who are
unable to attend the investigators' meeting. During this visit,
the CRA will review the following with the principal investigator
and his/her staff as appropriate:
- Study goals and obligations
- Investigator brochure
- Protocol procedures (with particular attention to
inclusion/exclusion criteria, enrollment goals, adverse events,
primary efficacy variables and GCP compliance)
- Informed consent procedure
- Randomization procedure
- AE/SAE reporting
- CRF completion and error correction/need for adequate source
documentation
- Maintenance of the investigator binder and site visit log
- Laboratory sample handling procedures and results reporting
procedures
- Clinical supply dispensation, accountability and storage
procedures
- Any other issue as deemed important to the conduct of the
study
Site Interims
The following issues are addressed at each interim visit as
appropriate:
- Informed consent
- Source document verification 100%
- CRF completion (may be done remotely)
- Expedient data retrieval and query resolution
- Drug accountability
- Check and review of the regulatory binder and its contents
- Clinical supply inventory
- SAE reporting
- Enrolment issues and targets
- Protocol amendments
- Significant protocol deviations
- Acceptability of facilities
- Personnel changes
- Updated regulatory documentation
- Laboratory sample handling
- Any other issue as deemed important to the conduct of the
study
Following each monitoring visit, CLINQUA will complete follow-up
letters and site visit reports within 10 working days of the site
visit date These follow-up letters and monitoring reports will be
forwarded to Sponsor on a monthly basis.
Preparation and submission of report on Serious Adverse
Events
Reporting serious adverse effects to the sponsor and to the FDA,
according to SOPs and FDA requirements
Preparation patient case narratives and SAE case narratives
Writing narrative descriptions of both significant and serious
adverse effects for inclusion in the Final Study Reports
Protocol review/input
Conduct literature searches as required Liaise with project
managers, Study Physicians and Investigators to ensure best study
design Co-ordinate with data management to ensure compliance with
internal systems Ensure protocol undergoes internal review as per
your company procedures
Informed Consent Form design
Assessing the completeness of Consent Form (review the Consent
Checklist) Assistance with the development of a project-specific
consent form
Study Manual development
Study Manual Preparation procedures to enhance performance
quality and consistency Altering study methodology as required